NIS to examine the effectiveness of TDC in patients with metastatic non-squamous NSCLC and high-risk genetic alterations - NAUTIC

Study identifier:D419MR00003

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Prospective non-interventional study (NIS) to examine the effectiveness of Tremelimumab + Durvalumab + platinum chemotherapy (TDC) in patients with metastatic non-squamous NSCLC and high-risk genetic alterations

Medical condition

non-squamous metastatic non-Small-Cell Lung Carcinoma

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

600

Study type

Observational

Age

18 Years - 120 Years

Date

Study Start Date: 28 Jun 2024
Estimated Primary Completion Date: 30 Jun 2028
Estimated Study Completion Date: 30 Jun 2028

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria